{"schemaVersion":"wpf-profile-export-v1","exportedAt":"2026-09-24T04:05:20.799Z","profile":{"slug":"liraglutide","name":"Liraglutide","aliases":[],"category":"GLP-1 receptor agonist"},"synthesis":{"mechanism":"Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist investigated in type 2 diabetes and weight management. WPF separates findings by dose, population, indication, comparator, and endpoint so that one result is not generalized to every setting.","evidence":"WPF’s existing Liraglutide research atlas includes directly attributable randomized studies: the LEADER cardiovascular outcomes trial in type 2 diabetes (PMID 27295427), a weight-management trial (PMID 26132939), and a pediatric obesity trial (PMID 39258838). It also includes a randomized comparison with semaglutide in weight management (PMID 35015037). These trials address distinct populations, regimens, and endpoints. A cardiovascular meta-analysis (PMID 37854744) is listed as a screening source, not a substitute for appraising the underlying trials.","safety":"This Directory entry has not yet converted its screening inventory into a fully source-linked editorial synthesis. Diabetes and weight-management studies use different populations, doses, and outcomes; pediatric findings require their own context. The absence of published citations in this Directory lane reflects its workflow state, not the absence of research.","observationalBoundary":"De-identified experiences in WPF’s observational archive are separate from controlled research. Such reports can motivate questions but cannot establish causation, efficacy, comparative safety, or event frequency.","openQuestions":"Which outcomes are supported by direct randomized trials in each indicated population? How do dose and comparator alter the interpretation of weight and cardiovascular outcomes? What remains uncertain about long-term safety and effects outside the studied populations? Source-level appraisal is needed before broader claims."},"completion":{"version":"wpf-profile-v1.1","verifiedSourceCount":0,"evidenceDepth":"limited_evidence","complete":false,"checks":[{"key":"overview","passed":true,"actual":257,"required":100,"severity":"blocking"},{"key":"evidence_summary","passed":true,"actual":558,"required":100,"severity":"blocking"},{"key":"safety_summary","passed":true,"actual":363,"required":100,"severity":"blocking"},{"key":"archive_boundary","passed":true,"actual":213,"required":75,"severity":"blocking"},{"key":"open_questions","passed":true,"actual":324,"required":75,"severity":"blocking"},{"key":"verified_sources","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"evidence_depth_target","passed":false,"actual":0,"required":25,"severity":"warning"},{"key":"reviewed_sources","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"chemistry","passed":false,"actual":false,"required":true,"severity":"blocking"},{"key":"regulatory_context","passed":false,"actual":0,"required":2,"severity":"blocking"},{"key":"claims","passed":false,"actual":0,"required":1,"severity":"blocking"},{"key":"claim_traceability","passed":true,"actual":0,"required":0,"severity":"blocking"},{"key":"regulatory_freshness","passed":true,"actual":0,"required":0,"severity":"warning"}],"failures":["verified_sources","evidence_depth_target","reviewed_sources","chemistry","regulatory_context","claims"]},"chemistry":null,"evidence":[],"regulatory":[],"claims":[],"correctionHistory":[],"boundaries":{"observationsAreEvidence":false,"completionIsPublicationApproval":false,"medicalAdvice":false}}